Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02176161 | Metformin Prostate Cancer Adjuvant Trial | completed | Phase 2 | 59 | NYU Langone HealthOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01717053 |
| Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer |
| completed |
| Phase 2 |
| 37 |
| Duke UniversityOTHER |
| 1 |
| Oct 10, 2022 |
| clinicaltrials |
| NCT02346526 | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 22 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT02789878 | Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | completed | Phase 2 | 64 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | completed | Phase 1 / Phase 2 | 43 | Rahul AggarwalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03279250 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | completed | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02716974 | A Study of Definitive Therapy to Treat Prostate Cancer(oligo-mets) | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04424654 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy(PSMA-BAT) | completed | Phase 2 | 20 | Hospital Sirio-LibanesOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 88 | University of ChicagoOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT02090114 | RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)(Restore) | completed | Phase 2 | 112 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00450411 | Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy | completed | Phase 2 | 100 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT02770391 | Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer | completed | Phase 2 | 54 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT00726596 | Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 64 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03392428 | A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer(TheraP) | completed | Phase 2 | 201 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT01434290 | Radiation Therapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 255 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT04475016 | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | completed | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03373006 | A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer | completed | Phase 2 | 20 | HALO DiagnosticsINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT00964002 | Efavirenz in Treating Patients With Metastatic Prostate Cancer(FAVE) | completed | Phase 2 | 61 | Institut BergoniéOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT02121639 | Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy(ProCAID) | completed | Phase 1 / Phase 2 | 160 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02268175 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02614859 | Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients(BIMET-1) | completed | Phase 2 | 29 | Fox Chase Cancer CenterOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01630590 | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT02353832 | Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer | completed | Phase 2 | 44 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT00828308 | Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer | completed | Phase 2 | 16 | Brown UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02678351 | 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery | completed | Phase 2 / Phase 3 | 74 | Andrei IagaruOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04862091 | Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
| NCT00589420 | Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03101046 | Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic(TACTIK) | completed | Phase 2 | 40 | UNICANCEROTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02601014 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7(STARVE-PC) | completed | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT01377753 | MR Image Guided Therapy in Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02673151 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | completed | Phase 2 / Phase 3 | 61 | Andrei IagaruOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02849990 | A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT00545766 | Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02737332 | A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer(STAAR) | completed | Phase 2 | 53 | Sun Pharmaceutical Industries LimitedINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT01751451 | 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy | completed | Phase 2 | 124 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02962284 | One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ | completed | Phase 2 | 20 | Sun Pharmaceutical Industries LimitedINDUSTRY | 0 | Nov 19, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT01252693 | International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer | completed | Phase 2 | 203 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01105130 | L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors | completed | Phase 2 | 140 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT02499497 | A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer | completed | Phase 2 | 114 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03062254 | Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy | completed | Phase 2 | 14 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Sep 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 24, 2022source: clinicaltrials